Telix Pharmaceuticals’ (TLX) Outperform Rating Reiterated at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Wednesday, September 23rd, Benzinga reports. They currently have a $22.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 94.00% from the company’s previous close.

Other analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Telix Pharmaceuticals has an average rating of “Buy” and a consensus price target of $20.50.

Telix Pharmaceuticals Trading Down 2.4%

TLX stock opened at $11.34 on Wednesday. The company’s fifty day simple moving average is $11.38 and its 200 day simple moving average is $10.55. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. purchased a new position in Telix Pharmaceuticals in the second quarter worth $1,731,000. Private Advisor Group LLC increased its stake in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the last quarter. XY Capital Ltd lifted its position in shares of Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares in the last quarter. Bank of America Corp DE raised its position in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.